Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 7/20 | 0.44 |
| ▸ | CCND1 | P24385 | 7/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327860 | 0.86 | HTR1A (0.46) | HTR1ACDK4CCND1CCNE2CCNE1 | |
| SCHEMBL23249531 | 0.79 | HTR1A (0.54) | HTR1ACDK4CCND1CCNE2CCNE1 | |
| SCHEMBL8657595 | 0.78 | HTR1A (0.48) | HTR1ACDK4CCND1CCNE2CCNE1 | |
| SCHEMBL23249326 | 0.76 | HTR1A (0.54) | HTR1ANISCHDRD2PARP1HTR3A | |
| SCHEMBL6327725 | 0.74 | HTR1A (0.46) | HTR1ACDK4CCND1CCNE2CCNE1 | |
| SCHEMBL23261784 | 0.72 | HTR1A (0.68) | HTR1ANISCHDRD2 | |
| SCHEMBL23261645 | 0.72 | DRD2 (0.57) | HTR1ANISCHDRD2 | |
| SCHEMBL6356879 | 0.72 | HTR1A (0.68) | HTR1ANISCHDRD2 | |
| SCHEMBL23249314 | 0.72 | HTR1A (0.68) | HTR1ANISCHDRD2 | |
| SCHEMBL31635823 | 0.72 | HTR1A (0.68) | HTR1ANISCHDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | HTR1A 3572/4885CDK4 3/4885CCND1 116/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | HTR1A 3530/4885CDK4 5/4885CCND1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.